PriceTargets.com logo

Cidara Therapeutics - CDTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $156.11
  • Forecasted Upside: -29.20%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$220.50 As of 12/4/2025 05:00 PM ET
▼ -0.48 (-0.22%)

This chart shows the closing price for CDTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cidara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDTX

Analyst Price Target is $156.11
▼ -29.20% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $156.11, with a high forecast of $200.00 and a low forecast of $46.00. The average price target represents a -29.20% upside from the last price of $220.50.

This chart shows the closing price for CDTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in Cidara Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2025GuggenheimDowngradeBuy ➝ Hold
11/17/2025Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform
11/17/2025JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
11/17/2025Morgan StanleyDowngradeOverweight ➝ Equal Weight
11/14/2025HC WainwrightDowngradeBuy ➝ Neutral
11/14/2025Needham & Company LLCDowngradeBuy ➝ Hold
11/7/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$137.00 ➝ $145.00
11/7/2025Needham & Company LLCBoost TargetBuy ➝ Buy$100.00 ➝ $135.00
10/21/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
10/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$150.00
10/16/2025Morgan StanleyInitiated CoverageOverweight$190.00
10/10/2025JPMorgan Chase & Co.Initiated CoverageOverweight$200.00
10/9/2025WBB SecuritiesBoost TargetStrong-Buy ➝ Strong-Buy$123.00 ➝ $199.00
10/9/2025HC WainwrightBoost TargetBuy ➝ Buy$110.00 ➝ $150.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/3/2025JMP SecuritiesSet TargetMarket Outperform ➝ Market Outperform$153.00 ➝ $173.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/26/2025HC WainwrightBoost TargetBuy ➝ Buy$74.00 ➝ $110.00
9/24/2025CitigroupReiterated RatingOutperform ➝ Outperform
9/24/2025JMP SecuritiesSet Target$153.00
9/24/2025GuggenheimSet TargetBuy ➝ Buy$70.00 ➝ $167.00
9/24/2025Royal Bank Of CanadaSet TargetOutperform ➝ Outperform$137.00
9/24/2025Needham & Company LLCBoost TargetBuy ➝ Buy$74.00 ➝ $100.00
9/22/2025WBB SecuritiesReiterated RatingStrong-Buy ➝ Strong-Buy$123.00 ➝ $123.00
9/22/2025WBB SecuritiesBoost TargetStrong-Buy ➝ Strong-Buy$45.00 ➝ $123.00
8/8/2025GuggenheimReiterated RatingBuy ➝ Buy
8/8/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$59.00 ➝ $66.00
8/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$53.00 ➝ $74.00
8/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$54.00 ➝ $74.00
7/9/2025GuggenheimSet Target$69.00
6/30/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$59.00
6/24/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform
6/24/2025Royal Bank Of CanadaUpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.00
6/24/2025GuggenheimSet TargetBuy ➝ Buy$50.00 ➝ $68.00
6/23/2025HC WainwrightReiterated RatingBuy ➝ Buy$41.00 ➝ $53.00
6/23/2025Needham & Company LLCBoost TargetBuy ➝ Buy$36.00 ➝ $54.00
6/23/2025WBB SecuritiesReiterated RatingStrong-Buy ➝ Strong-Buy$45.00
6/18/2025HC WainwrightUpgradeBuy$41.00
6/10/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
6/4/2025Needham & Company LLCBoost TargetBuy ➝ Buy$35.00 ➝ $36.00
6/2/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/27/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/23/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.00
5/23/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
5/16/2025GuggenheimBoost TargetBuy ➝ Buy$35.00 ➝ $50.00
5/9/2025GuggenheimBoost TargetBuy ➝ Buy$33.00 ➝ $35.00
5/9/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.00
4/29/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/12/2025CitigroupInitiated CoverageOutperform
3/12/2025JMP SecuritiesSet Target$46.00
3/12/2025Citizens JmpInitiated CoverageOutperform$46.00
3/10/2025HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $35.00
3/7/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/5/2025Cantor FitzgeraldUpgradeStrong-Buy
1/27/2025Cantor FitzgeraldReiterated RatingOverweight
12/13/2024Royal Bank Of CanadaInitiated CoverageOutperform$34.00
12/5/2024WBB SecuritiesBoost TargetStrong-Buy ➝ Strong-Buy$40.00 ➝ $45.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
11/8/2024GuggenheimInitiated CoverageBuy$33.00
10/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
8/14/2024Cantor FitzgeraldReiterated RatingOverweight
8/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
8/14/2024HC WainwrightUpgradeNeutral ➝ Buy$24.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
5/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00
4/25/2024WBB SecuritiesReiterated RatingStrong-Buy ➝ Strong-Buy$40.00
4/25/2024Needham & Company LLCBoost TargetBuy ➝ Buy$3.00 ➝ $25.00
4/23/2024Cantor FitzgeraldReiterated RatingOverweight
4/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
11/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
9/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
9/22/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
9/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
9/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
8/7/2023HC WainwrightReiterated RatingBuy$120.00
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
8/1/2023HC WainwrightReiterated RatingBuy$120.00
8/1/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00
3/23/2023HC WainwrightLower TargetBuy$130.00 ➝ $120.00
3/8/2023Cantor FitzgeraldReiterated RatingOverweight$100.00
3/1/2023HC WainwrightReiterated RatingBuy$130.00
1/25/2023HC WainwrightBoost TargetBuy$120.00 ➝ $130.00
5/12/2022HC WainwrightLower Target$150.00 ➝ $120.00
3/16/2022AegisReiterated RatingBuy
3/8/2022Needham & Company LLCReiterated RatingBuy$120.00
12/16/2021WedbushBoost TargetOutperform$100.00 ➝ $120.00
12/3/2021HC WainwrightInitiated CoverageBuy$120.00
9/22/2021AegisLower TargetBuy$180.00 ➝ $160.00
9/22/2021WBB SecuritiesUpgradeBuy ➝ Strong-Buy$125.00
3/4/2021AegisInitiated CoverageBuy$180.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 16 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 16 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 10 very positive mentions
  • 25 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 21 very positive mentions
  • 40 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 21 very positive mentions
  • 40 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $220.50
Low: $219.86
High: $220.69

50 Day Range

MA: $137.53
Low: $90.50
High: $220.74

52 Week Range

Now: $220.50
Low: $15.22
High: $221.20

Volume

453,521 shs

Average Volume

2,245,477 shs

Market Capitalization

$6.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Cidara Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Cidara Therapeutics in the last year: Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Royal Bank Of Canada, Wall Street Zen, WBB Securities, and Weiss Ratings.
View the latest analyst ratings for CDTX.

What is the current price target for Cidara Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cidara Therapeutics in the last year. Their average twelve-month price target is $156.11, suggesting a possible downside of 29.2%. JPMorgan Chase & Co. has the highest price target set, predicting CDTX will reach $200.00 in the next twelve months. Citizens Jmp has the lowest price target set, forecasting a price of $46.00 for Cidara Therapeutics in the next year.
View the latest price targets for CDTX.

What is the current consensus analyst rating for Cidara Therapeutics?

Cidara Therapeutics currently has 1 sell rating, 6 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CDTX, but not buy more shares or sell existing shares.
View the latest ratings for CDTX.

What other companies compete with Cidara Therapeutics?

Other companies that are similar to Cidara Therapeutics include BioNTech, Genmab A/S, Revolution Medicines, Roivant Sciences and BridgeBio Pharma. Learn More about companies similar to Cidara Therapeutics.

How do I contact Cidara Therapeutics' investor relations team?

Cidara Therapeutics' physical mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 752-6170 and its investor relations email address is [email protected]. The official website for Cidara Therapeutics is www.cidara.com. Learn More about contacing Cidara Therapeutics investor relations.